

Programme - Main Agenda Sessions

Thursday 5th June	
09:00 - 13:00	<p>Pre-conference sessions/meetings (by invitation only)</p> <ul style="list-style-type: none"> • NIT Meeting • Clinical Care Pathway Assessment (CARPA) Meeting • Nurse training - Fibroscan (Echosens)
13:00 - 14:00 Networking Lunch for attendees	
14:00 - 14:55	<p>Opening Remarks with the Think-tank directors: Jeffrey Lazarus, Jörn Schattenburg and Naim Alkhouri</p> <p>Keynote Address:</p> <ul style="list-style-type: none"> • Dr Francesco Branca, Professor, Institute of Global Health, University of Geneva, Switzerland • Xavier Cos, Corporate Innovation & Research Director, Institut Català de la Salut, Spain • Tit Albrecht, President, European Public Health Association, Switzerland • Ajay Duseja, Professor and Head, Department of Hepatology, Chandigarh, India
15:00 - 16:00 (60 mins)	<p>Session 1: Future-proofing Liver Health: Person-centred Preventive Strategies</p> <p>Moderators:</p> <ul style="list-style-type: none"> • A.G. (Onno) Holleboom, Endocrinologist and cardiovascular internist, Department of Vascular Medicine, Amsterdam UMC, The Netherlands • Shira Zelber-Sagi, Clinical Dietitian, University of Haifa, The Tel-Aviv Medical Center, Israel <p>This session will explore person-centred and preventative strategies and policies to manage the SLD public health threat. Key themes will include tackling the global obesity challenge; awareness-raising and leveraging health literacy efforts, combined with an exploration of the pivotal roles of nutrition, including access to healthy foods, and lifestyle changes in mitigating metabolic dysfunction. Participants will delve into preventive hepatology and barriers posed by the social and commercial determinants of health.</p>
16:00 - 16:15 Coffee and Networking	
16:15 - 17:15 (60 mins)	<p>Session 2: Doubling MASH Diagnoses by 2027: A Revolution in NITs</p> <p>Moderators:</p> <ul style="list-style-type: none"> • Naim Alkhouri, Chief Medical Officer. Chief of Transplant Hepatology / Director of the Fatty Liver Programme at Arizona Liver Health, USA • Maja Thiele, Professor of Hepatology, Department of Gastroenterology and Hepatology, Odense University Hospital and University of Southern Denmark <p>The challenge is set to double the number of MASH diagnoses by 2027! Can cutting-edge solutions make this ambitious goal a reality? We'll explore innovative solutions in use or development, from early-stage biomarkers and diagnostic performance in clinical trials; to the power of other advances in early detection. With a focus on NITs, the barriers and challenges to their use in the field, issues of cost-effectiveness and accessibility along with provider awareness, this session will uncover how we can tangibly revolutionise MASH diagnosis.</p>

<p>17:20 - 18:30 (70 mins)</p>	<p>Session 3: Power of Collaboration: Multidisciplinary Teams in Early Diagnosis and Risk Stratification</p> <p>Moderators:</p> <ul style="list-style-type: none"> • Scott Isaacs, Endocrinologist, Emory University School of Medicine / Adjunct Associate Professor of Medicine & President, American Assoc. of Clinical Endocrinology, USA • Holly Lofton, Clinical Associate Professor of Surgery/ Medicine at NYU Grossman School of Medicine / Director, Medical Weight Management Programme at NYU Langone Health, USA <p>In an increasingly challenging healthcare ecosystem, where prevention and early detection of NCDs is key to reducing the cost-burden to health systems, interdisciplinary collaboration is the holy grail. How can hepatologists collaborate effectively with primary care physicians, other metabolic-dysfunction specialists, nurses, nutritionists and patient advocates to optimise comprehensive, coordinated care for patients living with MASLD/MASH, leveraging each other's expertise to support, educate and empower patients? Panellists will discuss holistic care pathways; the benefits of integrating advanced, automated tools, and the challenges of embedding screening into routine primary care.</p>
<p>19:00 - 22:00 VIP Rooftop Dinner Reception for all attendees – la Casa de les Punxes.</p>	
<p>Friday 6th June</p>	
<p>09:00 - 09:30</p>	<p>Keynote Remarks</p>
<p>09:30 - 10:40 (70 mins)</p>	<p>Session 4: Navigating Treatments: Strategies for an Evolving Landscape</p> <p>Moderators:</p> <ul style="list-style-type: none"> • Maru Rinella, Gastroenterologist, Director, Metabolic and Fatty Liver Disease Dept, University of Chicago, USA • Jörn Schattenburg, Professor, Director. Department of Internal Medicine. Saarland University Medical Centre, Germany <p>The treatment landscape for fibrosing liver disease is undergoing a transformation with the emergence of innovative treatments and clinical advancements offering hope for MASLD/MASH patients. This session will discuss how industry, practitioners and patient advocates can leverage these evolving treatments with a focus on their ground-breaking potential in liver disease and key comorbidities.</p>
<p>10:45 - 11:45 (60 mins)</p>	<p>Session 5: Digital Transformation in SLD Care: Big data, AI and Personalised Solutions for Better Outcomes</p> <p>Moderators:</p> <ul style="list-style-type: none"> • Jordi Serrano Pons, Medical Doctor, Digital and Global Health Expert, Founder of P8 Health, Spain • Didac Mauricio, Department of Endocrinology & Nutrition. CIBERDEM, Hospital de la Santa Creu i Sant Pau. Professor, University of Vic. Central University of Catalonia, Spain <p>Discover the transformative potential of data and digital innovation in screening and managing liver disease. Our expert panel will delve into the latest in wearables, the digitally quantified self, AI-driven solutions, lifestyle change apps and clinical decision support systems which are revolutionising detection, management, and patient outcomes, whilst integrating the latest in behavioural change theory supporting practical digital implementation. Can automated risk stratification algorithms and seamless EMR integration make early screening tools more accessible for primary care providers and specialists alike?</p>
<p>11:45 - 12:00 Coffee and Networking</p>	
<p>12:00 - 13:15 (75 mins)</p>	<p>Session 6: Interactive Insights: Dynamic Open Space Session for Cutting-Edge Solutions</p> <p>This will not be a session to take sitting down! Moving around the room, all participants will engage with experts - and that includes each other - on 6 key questions. You'll learn which when you enter the room!</p>

13:15 - 14:15 Networking lunch for all attendees	
14:15 - 15:30 (75 mins)	<p>Session 7: Roundtable: A Deep Dive into SLD Policies and Regulatory Processes (in collaboration with EU-funded project LIVERAIM)</p> <p>Moderators:</p> <ul style="list-style-type: none"> • Jeffrey V. Lazarus, Professor, CUNY Graduate School of Public Health and Health Policy, NY, USA and the Barcelona Institute for Global Health (ISGlobal), Spain / Director, Mash Cities • Veronica Miller, PhD, Adjunct Professor IDV, Berkeley School of Public Health / Director, Forum for Collaborative Research, USA <p>Addressing the global public health crisis of MASLD/MASH requires effective policies and regulatory frameworks, but recognising SLD as one of the major non-communicable diseases would be a great starting point. 2025 is the year of the UN High-level meeting on NCDs, and this roundtable will tackle the tough question of how to get MASLD/MASH on the menu where it counts, highlighting access to new treatments, as well as the role of payors in enabling screening and linkage to care. Delving into the complexities and barriers in drug and diagnostic approvals, SLD Think-tank discussants will discern how to shape the future of SLD management through policy innovation and regulatory advancements.</p>
15:30 - 15:45 Coffee and Networking	
15:45 - 16:45 (60 mins)	<p>Session 8: Roundtable: Urban Solutions: Tackling SLD in City Environments</p> <p>Moderators:</p> <ul style="list-style-type: none"> • Meena Bansal, Chief, Division of Liver Diseases, Icahn School of Medicine, Mount Sinai, USA • Nikos Dedes, Patient Advocate, Greece <p>The prevalence of steatotic liver disease is driven by sedentary lifestyles, dietary challenges and limited access to preventive care. Our expert roundtable will examine how urban settings and policies can be transformed to address this growing public health threat. Discover how to empower citizens to become more physically active, and how the MASH Cities series is leading the way, supporting cutting-edge local solutions to metabolic dysfunction and better liver health for all.</p>
16:45 - 17:00	Closing Remarks – Jeffrey Lazarus